Please ensure Javascript is enabled for purposes of website accessibility

Why Amedisys Is Crashing 14.3% Today

By Todd Campbell - Updated Jul 26, 2017 at 2:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Government reimbursement rates may slip 0.4% in 2018, and that's pressuring stocks across the home healthcare industry.

What happened

After the Centers for Medicare and Medicaid Services (CMS) said it may reduce reimbursement for home healthcare by 0.4% in 2018, shares in Amedisys Inc. (AMED 2.38%) are losing 14.3% of their value at 1:45 p.m. EDT Wednesday.

So what

The CMS has issued a proposed rule updating the Medicare home health prospective payment system rates and wage index for 2018. The proposal would cut payments to home health agencies next year by 0.4%, or about $80 million. For perspective, CMS reduced payments by 0.7% in 2017.

A frustrated trader stares at his computer monitors.

IMAGE SOURCE: GETTY IMAGES.

That's potentially bad news for everyone in the industry, including Amedisys, which provides home health, hospice, and personal care to over 385,000 patients per year in 34 states.

While Amedisys makes money from hospice and other care services, home health is the big driver of its revenue and earnings. In the first quarter, home healthcare was responsible for $271 million of its $370 million in total revenue. Medicare is a major payer for home health services provided by the company, making up 73.4% of home health revenue in Q1.

Now what

The ever-changing payment structure for home healthcare makes this industry riskier than others. The reduction in payments for next year is smaller than this year's cut, but beginning in 2019, the CMS plans to completely revamp its payments model in a manner that could reduce payments by 4.3% on a non-budget-neutral basis, or by 2.2% on a partially budget-neutral basis.

The uncertainty associated with changes to payments creates short-term risk, but the demographics associated with aging baby boomers continues to provide support. Hopefully, Amedisys management can provide some additional context for how these changes may impact the company when it reports Q2 results after the closing bell today.

Todd Campbell has no position in any stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amedisys, Inc. Stock Quote
Amedisys, Inc.
AMED
$122.33 (2.38%) $2.85

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.